had to be easily measurable using currently available and commonly used databases (e.g. administrative databases, hospital discharge card, etc.).
In particular, each of the KPIs identified had to be "reliable", i.e. subject to the lowest number of systematic errors possible, and "representative", i.e. characterised by a close relationship with the phenomenon that it intends to evaluate (14) . The KPIs also had to meet two other requirements: "accessibility", or be easily measurable using the available information sources, and "operativity", or be easily applicable in the context to be evaluated, allowing identification of critical issues and monitor interventions (14) . For each KPI defined, the E.Pic.A. multidisciplinary panel was asked to: (i) provide a definition, (ii) explain the methodology behind its calculation, and (iii) indicate the target for evaluation.
The present study describes only analytic methodology and does not contain any medical information about an identifiable patient. The findings will be shared with other hospitals and will be disseminated to the scientific community at conferences.
Key performance indicators
A total of seven KPIs were identified to measure inappropriateness of healthcare services provided in the ICP in BC: three for examinations, two for surgery and two for treatment. The three KPIs related to examinations were aimed at estimating the inappropriateness of diagnostic tests performed in the pre-and post-index breast surgery phases. The two KPIs for surgery measured the inappropriateness of re-surgery during the time elapsed from the index breast surgery. The two KPIs for treatment measured inappropriateness when referred to the time of administration of adjuvant therapy (chemotherapy and/or hormonal therapy) and radiotherapy after the index breast surgery.
Since the date of execution of the index breast surgery (and relative index hospitalisation) represents the time reference for calculation of each of the seven KPIs, it was essential to provide a definition that also included identification criteria. First, since it is possible to identify new BC patients undergoing breast surgery each year, the E.Pic.A. multidisciplinary panel established that the time period during which breast surgery would be identified is the calendar year (January 1 to December 31). The index breast surgery procedure was then defined as the first hospital admission for (total or partial) resection surgery in the year of observation characterised by the concomitant presence of one of the diagnostic codes according to the International Classification of Diseases 9 th revision Clinical Modification (ICD-9-CM) and one of the surgical codes listed in Tables I and II . Thus, from the index breast surgery identified, the following were excluded: − all male patients; − patients less than 18 years of age at the index breast surgery; − in prevalent cases, at least one hospitalisation for BC (ICD-9-CM V10.3 or 174* or 233.0) as the main or secondary diagnosis in the period between 3 years and 6 months prior to the date of the index breast surgery; in the coming years, it seems reasonable to expect that no new financial resources will be made available to the INHS for expenditures on anti-cancer drugs, while the number of new diagnoses of cancer continues to grow (3, 4) . It thus becomes increasingly important to place greater attention on increasing the efficiency of how healthcare resources are allocated along Integrated Care Pathways (ICPs), with a view on eliminating waste and saving costs. According to a recent economic analysis, waste of resources (e.g. overuse of inappropriate health interventions) increases healthcare expenditure by more than 20% (5).
To guarantee the survival of universalistic health system in such a picture where growing health needs are accompanied by rising costs and risk of wastages, the key point is to give value to healthcare that, according to Sir M. Gray, involves optimal allocation of resources (allocative value), together with a radical recovery of efficiency in a context that guarantees an unchanged or, if possible, greater effectiveness (technical-professional value) in full compliance with the individual patient's value system (personal value) (6) .
In Italy, in consideration of its impact in terms of incidence (28%) and prevalence (23% of all cancer patients) in women (7), breast cancer (BC) is a paradigmatic oncological condition where one can study value along the care pathway.
In addition, BC is a complex clinical condition whose management requires a multidisciplinary approach. This has led to centralise the ICP by specialised BC units (BUs). BUs allow patients to face BC with the certainty that they will be followed by a multidisciplinary team of dedicated specialists, treated according to the highest standards and accompanied throughout the disease journey. The BU is therefore an excellent model of intervention, thanks to which adherence to shared treatment standards has improved, with outcomes of the overall treatment process that are standardised and multidimensional (8) .
With the aim of increased efficiency, it becomes essential to measure the performance of the various activities needed for the ICP in BC. In the past, several multidisciplinary groups of professionals in the BU have defined a minimum set of quality indicators to measure the clinical efficacy of the ICP of BC (9, 10) .
In the present study, we report the methodology developed by the E.Pic.A. (Economic Appropriateness of an Integrated Care Pathway) multidisciplinary panel (composed of clinicians, health management physicians, methodologists, IT experts), which is aimed at constructing an analytic process that allows evaluation of clinical and economic inappropriateness in BC by defining key performance indicators (KPIs) (11) .
Methods
In accordance with current guidelines of the Associazione Italiana di Oncologia Medica (AIOM) (12) and the National Comprehensive Cancer Network (13) , the E.Pic.A. multidisciplinary panel was asked to identify and define a series of KPIs that can be utilised to evaluate the potential inappropriateness of healthcare services in the ICP in BC. In order for the evaluation process to be homogeneously applied by all hospitals, the KPIs identified by the E.Pic.A. multidisciplinary panel
Examinations KPIs

KPI-1: pre-surgery
Definition. The first KPI evaluates the percentage of patients with stage I-II BC in whom, during 60 days prior to the index breast surgery, at least one of the following examinations was performed: hepatic ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), bone scan or positron emission tomography (PET). Lastly, to determine staging of the BC, which is fundamental in the measurement of KPIs, the E.Pic.A. multidisciplinary panel adopted the tumour, node, metastases (TNM) coding described in the AIOM 2017 guidelines (15) listed in Table III ; preference was given to pathological TNM staging, while clinical staging was used as an alternative. For each of the seven KPIs, the definitions, reference targets and calculation methods used by the E.Pic.A. multidisciplinary panel are provided. Stage IIIC All T N3 M0
Stage IV All T All N M1
M0 includes M0 (i+).
A pM0 designation is not valid; any M0 should be clinical. If a patient presents with M1 before neoadjuvant systemic therapy, the stage is considered IV and remains IV independently of the response to neoadjuvant therapy. The stage may change if diagnostic imaging reveals the presence of distant metastases, provided that they were performed within 4 months of diagnosis in the absence of disease progression and that the patient did not undergo neoadjuvant therapy. The "yc" and "yp" prefixes indicate the classification after neoadjuvant therapy. No staging is indicated if a complete pathological response is achieved (e.g. ypT0N0 cM0). *T1 includes T1mic. **T0 and T1 tumours with only micro-metastases to lymph nodes are excluded from stage IIA and classified as stage IB.
BC (defined according to Tab. III) who, within 60 days prior to the index breast surgery (defined according to the ICD-9-CM codes reported in Tabs. I and II), underwent at least one examination among those reported in Table IV . The denominator refers to the number of patients with stage I-II BC (defined according to Tab. III) and index breast surgery (defined according to the ICD-9-CM codes in Tabs. I and II).
KPI-2: post-surgery
Definition. The second KPI evaluates the percentage of patients with stage I-II BC in whom, during 60 days after the index breast surgery, at least one of the following examinations was performed: hepatic ultrasound, CT, MRI, bone scan or PET (Tab. IV). The percentage of patients with BC who underwent PET must also have been evaluated for stage III BC. Target. The percentage for KPI-2 should not exceed 5%. Calculation. The percentage must be calculated by indicating in the numerator the number of patients with stage I-II BC (defined according to Tab. III) who, within 60 days after the index breast surgery (defined according to the ICD-9-CM codes reported in Tabs. I and II), underwent at least one examination among those reported in Table IV . The denominator refers to the number of patients with stage I-II BC (defined according to Tab. III) and index breast surgery (defined according to the ICD-9-CM codes shown in Tabs. I and II).
KPI-3: follow-up
Definition. The third KPI evaluates the percentage of patients with stage I-II BC who, starting from 60 days after the index breast surgery and up to 365 days after this surgery, underwent at least one of the following examinations: CT, MRI, bone scan or PET (Tab. IV).
Target. The percentage for KPI-3 should not exceed 5%.
Calculation. The percentage must be calculated by indicating in the numerator the number of patients with stage I-II BC (defined according to Tab. III) who, starting from 60 days after the index breast surgery (defined according to the ICD-9-CM codes in Tabs. I and II) and up to 365 days after this surgery, underwent at least one of the examinations indicated in Table IV , except for hepatic ultrasound. The denominator refers to the number of patients with stage I-II BC (defined according to Tab. III) and index breast surgery (defined according to the ICD-9-CM codes shown in Tabs. I and II).
Surgery KPIs
KPI-4: subsequent breast reconstruction/axillary dissection
Definition. The fourth KPI evaluates the percentage of patients with BC who, within 90 days of the index mastectomy, underwent subsequent surgery for breast reconstruction and/or axillary dissection. Table V shows the ICD-9-CM codes selected by the E.Pic.A. multidisciplinary panel to identify breast reconstruction and axillary dissection.
Target. The percentage for KPI-4 should be close to 0%. Calculation. The percentage must be calculated by indicating in the numerator all patients with BC who, within 90 days of the index mastectomy (defined according to the ICD-9-CM codes in Tab. I and ICD-9-CM codes 85.4* in Tab. II), underwent subsequent surgery for breast reconstruction and/or axillary dissection (defined by the ICD-9-CM codes in Tab. V). The denominator refers to the number of patients with BC and index mastectomy (defined according to the ICD-9-CM codes in Tab. I and ICD-9-CM codes 85.4* in Tab. II).
When possible, KPI-4 must be evaluated by subgrouping the subsequent surgery by breast reconstruction (KPI-4a) and axillary dissection (KPI-4b).
KPI-4a: subsequent breast reconstruction
Definition. KPI-4a evaluates the percentage of patients with BC who, within 90 days of the index mastectomy, underwent subsequent surgery for breast reconstruction.
Target. The percentage for KPI-4a should be close to 0%. Calculation. The percentage must be calculated by indicating in the numerator all patients with BC who, within 90 days of the index mastectomy (defined according to the ICD-9-CM codes reported in Tab. I and ICD-9-CM codes 85.4* in Tab. II), underwent subsequent surgery for breast reconstruction (defined as ICD-9-CM 85.7, 85.8 and 85.8* in Tab. V). The denominator refers to the number of patients with BC and index mastectomy (defined according to the ICD-9-CM codes in Tab. I and ICD-9-CM codes 85.4* in Tab. II).
KPI-4b: subsequent axillary dissection
Definition. KPI-4b evaluates the percentage of patients with BC who, within 90 days of the index mastectomy, underwent subsequent surgery for axillary dissection.
Target. The percentage for KPI-4a should be close to 0%. Calculation. The percentage must be calculated by indicating in the numerator all patients with BC who, within 90 days of the index mastectomy (defined according to the ICD-9-CM codes reported in Tab. I and ICD-9-CM codes 85.4* in Tab. II), underwent subsequent surgery for axillary dissection (defined by code ICD-9-CM 40.51 in Tab. V). The denominator refers to the number of patients with BC and index mastectomy (defined according to the ICD-9-CM codes in Tab. I and ICD-9-CM codes 85.4* in Tab. II).
KPI-5: subsequent surgery
Definition. This KPI evaluates the percentage of patients with BC who underwent a subsequent surgery within 120 days following a conservative (partial resection) index breast surgery.
Target. The percentage of KPI-5 should be close to 0%. Calculation. The percentage must be calculated by indicating in the numerator all patients with BC who underwent a subsequent surgery (defined according to the ICD-9-CM codes in Tabs. I and II) within 120 days following a conservative (partial resection) index breast surgery (defined by the ICD-9-CM codes in Tab. I and ICD-9 codes in Tab. II, excluding those for ICD-9-CM mastectomy 85.4*), excluding patients 
Treatment KPIs
KPI-6: treatment timing
Definition. The sixth KPI evaluates the percentage of patients with BC who, as candidates for chemotherapy and/or hormone therapy and without evidence of disease, initiated adjuvant treatment (chemotherapy and/or hormone therapy as the only pharmacological therapy in the adjuvant setting) within 60 days of the index breast surgery. The strategy defined by the E.Pic.A. multidisciplinary panel to calculate KPI-6 focused on identification of all administrations of chemotherapy and/or hormone therapy subsequent to the date of the index breast surgery. Table VI lists the sources and the codes to identify administrations of chemotherapy and/or hormone therapy. Target. The percentage of KPI-6 should be close to 100%. Calculation. The percentage must be calculated by indicating in the numerator all patients with BC who, as candidates for chemotherapy and/or hormone therapy and without evidence of disease, initiated adjuvant treatment (chemotherapy and/or hormone therapy with the codes in Tab. VI) within 60 days from the index breast surgery (ICD-9-CM codes in Tabs. I and II). The denominator refers to the number of patients with BC who, as candidates for chemotherapy and/ or hormone therapy and without evidence of disease, began adjuvant treatment (chemotherapy and/or hormone therapy with the codes in Tab. VI) within 180 days from the index breast surgery (defined according to the ICD-9-CM codes shown in Tabs. I and II). The calculation of the KPI is referred to the following time intervals: 0-30 days, 31-45 days, 46-60 days, 61-90 days and 90-180 days. Whenever possible, KPI-6 must be evaluated by subgrouping the treatment by chemotherapy (KPI-6a) and hormone therapy (KPI-6b).
KPI-6a: chemotherapy timing
Definition. KPI-6a evaluates the percentage of patients with BC who, as candidates for chemotherapy and without evidence of disease, started adjuvant chemotherapy within 60 days of the index breast surgery.
Target. The percentage of KPI-6a should be close to 100%. Calculation. The percentage must be calculated by indicating in the numerator all patients with BC who, as candidates for chemotherapy and without evidence of disease, started chemotherapy in the adjuvant setting (codes in Tab. VI) within 60 days of the index breast surgery (defined by ICD-9-CM codes in Tabs. I and II). The denominator refers to the number of patients with BC who, as candidates for chemotherapy and without evidence of disease, started chemotherapy in the adjuvant setting (codes in Tab. VI) within 180 days from the index breast surgery (defined according to the ICD-9-CM codes in Tabs. I and II). Calculation of the KPI is referred to the following time intervals: 0-30 days, 31-45 days, 46-60 days, 61-90 days and 90-180 days.
KPI-6b: hormone therapy timing
Definition. KPI-6b evaluates the percentage of patients with BC who, as candidates for hormone therapy and without evidence of disease, started hormone therapy in the adjuvant setting within 60 days of the index breast surgery.
Target. The percentage of KPI-6b should be close to 100%. Calculation. The percentage must be calculated by indicating in the numerator all patients with BC who, as candidates for hormone therapy and without evidence of disease, started hormone therapy in the adjuvant setting (identification codes in Tab. VI) within 60 days of the index breast surgery (defined by the ICD-9-CM codes in Tabs. I and II). The denominator refers to the number of patients with BC who, as candidates for hormone therapy and without evidence of disease, started hormone therapy in the adjuvant setting (codes in Tab. VI) within 180 days from the index breast surgery (defined according to the ICD-9-CM codes in Tabs. I and II). Calculation of the KPI is referred to the following time intervals: 0-30 days, 31-45 days, 46-60 days, 61-90 days and 90-180 days.
KPI-7: radiotherapy timing
Definition. The last KPI evaluates the percentage of patients with BC who underwent partial resection surgery and who, as candidates for radiotherapy, initiated radiotherapy within 180 days of the last surgery, if no adjuvant treatment was administered, or within 270 days, if adjuvant treatment was administered. Table VII lists the codes identified by the E.Pic.A. multidisciplinary panel for radiotherapy.
Target. The percentage of KPI-7 should be close to 100%. Calculation. The percentage must be calculated by indicating in the numerator all patients with BC who, as candidates for radiotherapy, received at least one radiotherapy session (Tab. VII) within 180 days of the last partial resection surgery (based on ICD-9-CM codes in Tab. I and ICD-9 codes in Tab. II, excluding those for ICD-9-CM mastectomy 85.4*), if no adjuvant therapy was administered, or within 270 days, if adjuvant therapy was given. The denominator refers to the number of patients with BC who, as candidates for radiotherapy, began at least one radiotherapy session (identification codes in Tab. VII) within 365 days from the last partial resection surgery (according to the ICD-9-CM codes reported in Tab. I and ICD-9-CM codes in Tab. II, excluding those for mastectomy 85.4*).
Discussion and conclusions
The methodology developed by the E.Pic.A. multidisciplinary panel in the present study evaluated the ICP of BC patients, and identified a set of KPIs that examine some of the most critical factors related to the efficiency of a process or particular activity (11) .
It is likely that one of the biggest problems with the INHS is the cascading effect of the decision-making process combined with poor overall accountability of the system. The public payor is different from those who prescribe (clinicians) and, without adequate planning and structuring of the INHS, the process of allocating resources often becomes complex and flawed, making it impossible to efficiently use the available resources. Therefore, providing tools to guide the treatment pathway for both economic (general managers) and clinical (clinicians) decision makers represents the attempt to bridge the gap between those who prescribe and those who are in charge of economic resources. In this light, clinical/administrative data are useful for constructing an accurate representation of real-word practice, in which all the different stakeholders who provide healthcare services can make their own evaluations in a systematic manner.
As already indicated herein, within a context characterised by ever-increasing healthcare needs, it would be impracticable to believe that increasing resources will become available in the near future. Hence, the E.Pic.A. multidisciplinary panel developed a methodology to identify inappropriate (or potentially inappropriate) activities that allow, within a specified ICP, reduction of waste so that new resources can be made available. The application of this methodology should allow achievement of short-term (reduction of inappropriateness), medium-term (ensure clinical outcomes while reducing waste) and long-term (reduce waiting lists and increase availability of healthcare technologies) objectives. This would thus increase the value of the healthcare services provided by the INHS. In fact, by improving allocation of resources in relation to burden of illness and need for healthcare, it is possible to increase the performance of both hospitals and professionals (technical-professional value), in line with the highest expectations of each individual patient (personal value).
Compared to the core set of parameters defined by EU-SOMA (European Society of Breast Cancer Specialists) (9), composed of 17 indicators to evaluate quality of treatment pathways for BC, the seven KPIs defined by the E.Pic.A. multidisciplinary panel are mainly aimed at identification of potential inappropriateness related to providing unnecessary services during the ICP of BC. Specifically, the methodology attempts to identify potential areas with low "value" in terms of utilisation of resources, and reducing the associated costs. An initial and partial application of this methodology has recently been carried out at the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST of Meldola (Forlì, Italy) (17) . The study estimated that the hospital provided 2,516 inappropriate examinations (from January 2010 to June 2016) with a total cost of about €580,000.
The present methodology will be applied at regional (Agenzia Regionale di Sanità Toscana, Istituto per lo studio, la prevenzione e la rete oncologica Toscana, and Azienda Sanitaria Locale CN2 Piemonte) and local levels (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST of Meldola, Forlì, Italy and Istituto di Sanità Pubblica Sezione di Igiene dell'Università Cattolica del Sacro Cuore, Rome, Italy) with the aim to provide a more complete picture of inappropriateness and waste, allowing resources to be redirected towards more valuable interventions/examinations for patients with BC (not only), and close the gap between correct use of resources and achieving the best clinical results. 
